



Adherium presents its Smartinhaler™ data at Respiratory Drug Delivery Europe 2017

Melbourne, Australia, 27 April 2017, Adherium Limited (ASX: ADR, 'Adherium'), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, will today present data on its proprietary Smartinhaler™ platform at the Respiratory Drug Delivery Europe conference 2017 (RDD Europe).

Adherium's Group CEO, Garth Sutherland, will present 'Track and Remind: Can Connected Devices Improve Patient Medication Adherence?', focusing on the recognized problem of adherence to preventative medication and how Adherium's Smartinhaler™ platform has demonstrated its ability to improve patient engagement and treatment effectiveness.

The presentation coincides with the publication of the above titled article in RDD's peer reviewed journal Respiratory Drug Delivery Europe 2017 [<http://www.rddonline.com>]. RDD Europe brings together pulmonary and nasal drug delivery experts from all around the world to exchange scientific knowledge and expertise, and also provides a dynamic forum for expanded opportunities for business.

The Smartinhaler™ platform comprises a connected digital sensor device, which fits discreetly onto asthma inhalers, apps that connect with the device to help patient track medication usage and provide reminders, and cloud-based software for analysis of patient medication usage data by caregivers and clinicians.

Adherium's vision is to revolutionise healthcare by creating meaningful solutions that transform lives. The presentation will draw on Adherium's independent data across four published clinical trials, all of which showed that the Smartinhaler™ reminder significantly improved medication adherence, resulting in a reduction of asthma related exacerbations, fewer trips to hospitals and less time off school or work, allowing people to have more control over the amount of time and effort they need to invest in their respiratory condition.

The Smartinhaler™ platform can also help identify cost savings using insights on treatment efficacy, lowering the overall treatment burden and more cost effectively manage patients' chronic respiratory conditions. With such positive outcomes from the introduction of the Smartinhaler™ technology, this approach should be used in patients where the disease has proved difficult to control, and in all patients at some stage to clarify the diagnosis of the balance between disease and drug use.

Garth Sutherland, Group CEO of Adherium said: *"The extensive research and knowledge base that we have built supporting our Smartinhaler™ platform is enabling open and honest discussion about medication usage to improve adherence and self-management of respiratory diseases. Through our contribution to the Asthma UK 'Smart Asthma' report, our work with Europe-wide initiatives such as the myAirCoach programme and NICE's acknowledgement of the Smartinhaler™ platform, we continue to lead the respiratory medication adherence space."*

ABOUT ADHERIUM

Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.

Adherium operates globally from bases in the USA, Europe and Australasia.

Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. The Company's proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.

The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

www.adherium.com www.smartinhaler.com

Enquiries:

At Adherium:	Media enquiries:
Investor Relations at Adherium: Julia Chambers Head of Corporate Development M: +64 27 807 8153 E: investors@adherium.com	
Rest of World Erin Wansbrough Vice President Business Development Rest of World M: +64 21 766 083 E: erinw@adherium.com	Australia and New Zealand Rudi Michelson Monsoon Communications D: +61 3 9620 3333 E: rudim@monsoon.com.au
North America James Hattersley Senior Vice President Business Development North America M: +1 610 955 5886 E: jamesh@adherium.com	North America Erich Sandoval Lazar Partners D: +1 213-908-6226 E: esandoval@lazarpartners.com
Europe Scott Fleming Senior Vice President Business Development Europe M: +31 646 876 989 E: scottf@adherium.com	Europe Sue Charles/Tim Watson Instinctif Partners D: +44 20 7457 2020 E: adherium@instinctif.com